Brentuximab a novel antibody therapy: real-world use confirms efficacy and tolerability for CD30-positive cutaneous lymphoma

Br J Dermatol. 2020 Mar;182(3):799-800. doi: 10.1111/bjd.18535. Epub 2019 Nov 7.

Authors

S Engelina¹, M Saggu¹, J Yoo¹, F Shah¹, A Stevens¹, C Irwin¹, S Chaganti¹, J J Scarisbrick¹

Affiliation

¹ University Hospital Birmingham (UHB), Birmingham, U.K.

PMID: 31529492
DOI: 10.1111/bjd.18535

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents* / adverse effects
Brentuximab Vedotin
Humans
Immunoconjugates* / adverse effects
Ki-1 Antigen
Lymphoma, Non-Hodgkin*

Substances

Antineoplastic Agents
Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin